MONROVIA, Calif., Dec. 19, 2017 /PRNewswire/ -- Xencor, Inc.
(NASDAQ: XNCR), a clinical-stage biopharmaceutical company
developing engineered monoclonal antibodies for the treatment of
autoimmune diseases, asthma and allergic diseases and cancer, today
announced the appointment of Richard
Ranieri to its board of directors.
"Mr. Ranieri has a wealth of experience building biotechnology
companies through major growth phases and the transition from
research and development to commercial stage," said Bassil Dahiyat, Ph.D., president and chief
executive officer of Xencor. "Mr. Ranieri's knowledge of the
industry, its people and how biotech organizations should be
managed to attract, retain, and engage their human capital will
help to fill an important organization development role on Xencor's
board. He will be a tremendous asset by helping us build our team
to execute our ambitious plans to advance our clinal-stage programs
and bispecific oncology pipeline."
"I am looking forward to working with the Xencor team to
leverage the XmAb technology and the broad and innovative pipeline
they have built," said Mr. Ranieri. "This is an exciting time to be
a part of a biotech such as Xencor advancing a robust pipeline and
powerful technology platform."
Mr. Ranieri has more than twenty years of senior level biopharma
human resources leadership and currently serves as executive vice
president of human resources and corporate affairs at BioMarin,
where he manages and directs human resources worldwide. Prior to
this role he served as executive vice president, human resources at
Dendreon Corporation, and executive vice president, human resources
& administration at Sepracor, Inc. Earlier in his career, Mr.
Ranieri served in executive positions at Neurocrine Biosciences,
Inc., Genencor International, and Smithkline Beecham. He received a
B.A. from Villanova University, and an
M.A. in organizational development from Rider
University.
About Xencor, Inc.
Xencor is a clinical-stage
biopharmaceutical company developing engineered monoclonal
antibodies for the treatment of autoimmune diseases, asthma and
allergic diseases and cancer. Currently, 11 candidates engineered
with Xencor's XmAb® technology are in clinical
development internally and with
partners. Xencor's internal programs include: XmAb®5871
in Phase 2 development for the treatment of IgG4-Related Disease,
and also for the treatment of Systemic Lupus Erythematosus;
XmAb®7195 in Phase 1 development for the treatment of asthma and
allergic diseases; XmAb®14045 in Phase 1 development for acute
myeloid leukemia; XmAb®13676 in Phase 1 development for B-cell
malignancies; XmAb®18087 in pre-clinical development for the
treatment of neuroendocrine tumors; and XmAb®20717 in pre-clinical
development for the treatment of multiple
cancers. Xencor's XmAb antibody engineering technology
enables small changes to the structure of monoclonal antibodies
resulting in new mechanisms of therapeutic
action. Xencor partners include Novartis, Amgen,
MorphoSys, Merck, CSL/Janssen, Alexion and Boehringer
Ingelheim. For more information, please
visit www.xencor.com.
Forward Looking Statements:
Statements contained in
this press release and the related abstracts and presentations
regarding matters that are not historical facts are forward-looking
statements within the meaning of applicable securities laws,
including any expectations relating to our business, research and
development programs, partnering efforts or our capital
requirements. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements and the timing of events to be
materially different from those implied by such statements, and
therefore these statements should not be read as guarantees of
future performance or results. Such risks include, without
limitation, the risks associated with the process of discovering,
developing, manufacturing and commercializing drugs that are safe
and effective for use as human therapeutics and other risks
described in Xencor's public securities filings. All
forward-looking statements are based on Xencor's current
information and belief as well as assumptions made by Xencor.
Readers are cautioned not to place undue reliance on such
statements and Xencor disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
View original content with
multimedia:http://www.prnewswire.com/news-releases/xencor-appoints-richard-ranieri-to-board-of-directors-300572949.html
SOURCE Xencor, Inc.